Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 September 2022 | Story Leonie Bolleurs | Photo Johané Odendaal and Edward Lee
UFS Solar car
Team UFS entered the Sasol Solar Challenge for the very first time this year, competing with seven other teams and showcasing their technological input and innovation.

Excitement. Nervousness. A thousand thoughts going through our minds, but primarily “Are we really ready for the challenges that lie ahead?” and “What did we get ourselves into?” In the moments leading up to this year’s Sasol Solar Challenge, these were the thoughts and emotions of Team UFS, who entered their solar car, Lengau.

“But I had confidence in the team,” says Dr Hendrik van Heerden from the UFS Department of Physics at the University of the Free State (UFS) and project manager of Team UFS who entered the challenge for the very first time this year.

Testing perseverance

Entering the Sasol Solar Challenge – a biennial competition that has been running since 2008 – Team UFS competed against seven other teams (representing local and international universities, high schools, and engineering teams), sharing the public roads of South Africa with trucks and regular traffic, sometimes experiencing steep mountain climbs, testing not only their technological input and innovation, but also their perseverance over an eight-day period. 

“One of our main challenges was the long time on the road, to which the heavy weight of the solar car, efficiency of the solar panels, and the effective charging of the battery contributed,” says Dr Van Heerden, stating that these problems were difficult to tackle with the small budget they had. “We, however, stayed positive and was determined to pull through.” 

“We were also open for learning from the other teams, the scrutineers, and observers regarding the mechanical, electrical, and body of competing solar cars. Thus, building knowledge and collaborating is a success we celebrate,” he adds.

In the end it paid off, as Team UFS completed the race, covering a distance of more than 500 km and ending in seventh place overall. The team that finished with the greatest distance covered within the allotted time won the challenge, in this instance the Brunel Solar Team, covering 4 228,2 km.

Dr Van Heerden believes that they did exceptionally well for a debut team, proving themselves against the best. “I am of the opinion that this challenge made us stronger and gave each of us a new perspective on how we should approach life,” he adds.

“As we are all enthusiastic about science and engineering, this challenge inspired us to build towards a future where renewable energy could be an important source of energy in South Africa.”
For a debut team, we did exceptionally well, proving ourselves against the best. – Dr Hendrik van Heerden.

Learning the ropes

The teams left Carnival City in Johannesburg on 9 September 2022 and arrived at the finish line at the V&A Waterfront in Cape Town on Friday 16 September 2022.

Talking about the next race, Dr Van Heerden says he wants to build a better, more effective solar car. “We strive to continuously improve the design, technology, and science going into our car,” he says. 

“For this challenge, we were interested in learning about the mechanical, electrical, and overall body of a solar car. Hence, our solar vehicle was designed well enough to participate and reliable enough to succeed.”

According to him, their focus will shift to competing against the other teams for the next Sasol Solar Challenge. “We will also be more prepared, since we now know what to expect from the challenge. It was our first time participating in the Sasol Solar Challenge, and we’ve learnt so much from the past two weeks – we will carry that forward to the next challenge.

 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept